Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00080483 · ClinicalTrials.gov registry record · Phase 2
Testosterone and Growth Hormone for Bone Loss in Men
A Phase 2 study of Hypogonadism and Growth Hormone Deficiency, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT00080483: Completed Phase 2 study of Hypogonadism and Growth Hormone Deficiency, sponsored by University of Pennsylvania.
NCT00080483 is a Phase 2 study of Hypogonadism and Growth Hormone Deficiency that has completed, run by University of Pennsylvania. The registered enrollment target is 35 participants, below the 119-participant average among 21 other Hypogonadism trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00080483, a Phase 2 study of Hypogonadism and Growth Hormone Deficiency, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
Deficiency of testosterone, growth hormone, or both hormones can result in osteoporosis. If either hormone is replaced, the condition of the bones improves. The purpose of this study is to determine if dual hormone treatment for men deficient in testosterone and growth hormone improves bone structure more than testosterone treatment alone.
Primary Outcome
Increased bone volume fraction (the fraction of bone that is bone, as opposed to the fraction that is marrow), as determined by magnetic resonance of the distal tibia
Conditions Studied
Interventions
- DRUG Testosterone plus somatropin
- DRUG testosterone
Study Locations (1)
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2004-03 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
What the finished NCT00080483 record still lists
NCT00080483 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 119-participant average among 21 other Hypogonadism trials with a reported enrollment target (71% lower).
The record links to 3 conditions, with Hypogonadism appearing as the primary indexed condition, and to 2 interventions - of which Testosterone plus somatropin is the first listed.
NCT00080483 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00080483 about?
NCT00080483 is a clinical study titled "Testosterone and Growth Hormone for Bone Loss in Men". Deficiency of testosterone, growth hormone, or both hormones can result in osteoporosis. If either hormone is replaced, the condition of the bones improves. The purpose of this study is to determine if dual hormone treatment for men deficient in testosterone and growth hormone improves bone structur...
What is the current status of trial NCT00080483?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2004-03. Estimated completion is 2010-09.
What conditions does trial NCT00080483 study?
This clinical trial studies the following conditions: Hypogonadism, Growth Hormone Deficiency, Hypopituitarism.
What interventions are being tested in trial NCT00080483?
The interventions under investigation include: Testosterone plus somatropin (DRUG), testosterone (DRUG).
Who is sponsoring clinical trial NCT00080483?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00080483 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypogonadism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00080483's enrollment target sits among peer trials
35 16th of 21 higher than 6 of 21 other Hypogonadism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypogonadism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury
RECRUITING · Phase 2
-
A Preliminary Clinical Study to Evaluate Fispemifene in the Treatment of Hypogonadism
COMPLETED · Phase 2
-
Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems
COMPLETED · Phase 2
-
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
COMPLETED · Phase 2
-
The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate
COMPLETED · Phase 2
-
Observation of Environment and Reproductive-Endocrine Effects
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia